Providing Market Intelligence for 40 Years

In The News

Netflix Reports Lowest Churn As Fifth Of US Broadband Households Cancel OTT In 2015

According to research from Parks Associates, a fifth of broadband US households have cancelled at least one over-the-top (OTT) video service in the past 12 months, up two percentage points from a year ago.

Brett Sappington, senior director of research at Parks, said that Netflix is still the OTT leader in the US, with 52% of all US broadband households subscribing to the service at the end of 2015. Netflix also had the lowest churn rate as a percentage of its total subscriber base. In the past 12 months, just 5% of US broadband households cancelled their Netflix account, including those who cancelled at the end of the trial period. That figure represents 9% of the company’s current subscriber base.

From the articles "Netflix Reports Lowest Churn As Fifth Of US Broadband Households Cancel OTT In 2015" by Michelle Clancy.
 

Previously In The News

AT&T kills Plenti loyalty program but touts ongoing Thanks campaign

Parks Associates reported last year that 60% of respondents in a survey valued a rewards program for being a loyal customers, third only to the ability to roll over unused data (66%) and free access t...

One in five US subscribers now ‘dissatisfied’ with pay TV service

Some 20% of US pay TV subscribers are now dissatisfied with their pay TV service, according to research from Parks Associates. The future represents a 100% increase since 2013, according to Parks....

AT&T gooses $45 prepaid plan with cheaper iPhones

And, as a recent report from Parks Associates noted, consumers are increasingly drawn to the simplified pricing offers in prepaid. The firm said that “currently postpaid carriers are starting to explo...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...